Document is current
Any future updates will be listed below
-
Authors
Longarini, Edoardo José https://orcid.org/0000-0003-3919-1169
Matić, Ivan https://orcid.org/0000-0003-0170-7991
- License Information
-
More Information
Article History
Received: 11 January 2024
Accepted: 26 April 2024
First Online: 18 May 2024
Competing interests
: The authors E.J.L. and I.M. declare the following competing financial interest: Max-Planck-Innovation, which is responsible for technology transfer from Max Planck Institutes, has licensed the antibodies AbD33205, AbD33644, AbD34251 and AbD43647 to Bio-Rad Laboratories, which markets them for research purposes.
